ATE412408T1 - Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie - Google Patents

Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie

Info

Publication number
ATE412408T1
ATE412408T1 AT03730049T AT03730049T ATE412408T1 AT E412408 T1 ATE412408 T1 AT E412408T1 AT 03730049 T AT03730049 T AT 03730049T AT 03730049 T AT03730049 T AT 03730049T AT E412408 T1 ATE412408 T1 AT E412408T1
Authority
AT
Austria
Prior art keywords
receptor binding
cancer therapy
edg receptor
binding ingredients
sphingosine
Prior art date
Application number
AT03730049T
Other languages
German (de)
English (en)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth La
Peter Lassota
Diana Mechtcheriakova
Jeanette Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE412408T1 publication Critical patent/ATE412408T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03730049T 2002-05-16 2003-05-15 Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie ATE412408T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24

Publications (1)

Publication Number Publication Date
ATE412408T1 true ATE412408T1 (de) 2008-11-15

Family

ID=29554311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730049T ATE412408T1 (de) 2002-05-16 2003-05-15 Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie

Country Status (22)

Country Link
US (2) US20090209495A1 (enExample)
EP (3) EP1505959B1 (enExample)
JP (3) JP5227492B2 (enExample)
KR (1) KR20120125398A (enExample)
CN (1) CN1652757B (enExample)
AT (1) ATE412408T1 (enExample)
AU (1) AU2003240655B2 (enExample)
BR (1) BR0311173A (enExample)
CA (1) CA2483594C (enExample)
CY (1) CY1108719T1 (enExample)
DE (1) DE60324416D1 (enExample)
DK (1) DK1505959T3 (enExample)
ES (1) ES2316758T3 (enExample)
IL (3) IL164838A (enExample)
MX (1) MXPA04011384A (enExample)
NO (2) NO334074B1 (enExample)
NZ (2) NZ560662A (enExample)
PL (1) PL372103A1 (enExample)
PT (1) PT1505959E (enExample)
SI (1) SI1505959T1 (enExample)
WO (1) WO2003097028A1 (enExample)
ZA (1) ZA200408575B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
PL211954B1 (pl) 2002-01-11 2012-07-31 Sankyo Co Związek, kompozycja farmaceutyczna oraz zastosowanie kompozycji farmaceutycznej
CA2488425A1 (en) 2002-06-07 2003-12-18 Es Cell International Pte Ltd Methods of regulating differentiation in stem cells
CN100344638C (zh) * 2003-02-18 2007-10-24 杏林制药株式会社 氨基膦酸衍生物、其加成盐以及s1p受体调节剂
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1798226A4 (en) 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd TRAIZOL DERIVATIVE
JP2008509931A (ja) 2004-08-13 2008-04-03 プレーシス ファーマスーティカルズ インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物
EP1812797B1 (en) * 2004-10-28 2013-03-20 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
RU2409570C2 (ru) 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
WO2007091570A1 (ja) 2006-02-06 2007-08-16 Taisho Pharmaceutical Co., Ltd. スフィンゴシン－１－リン酸結合阻害物質
EP2004234A2 (en) * 2006-04-06 2008-12-24 Novartis AG Combination of organic compounds
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP2083862A4 (en) * 2006-10-27 2012-09-19 Lpath Inc COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
CN101790517B (zh) 2007-08-01 2013-08-21 大正制药株式会社 抑制s1p1结合的物质
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
PT2356090T (pt) * 2008-11-11 2017-10-16 Novartis Ag Formas cristalinas de fingolimod, hcl
HRP20151190T1 (hr) 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2456752A2 (en) * 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20120264719A1 (en) 2009-09-29 2012-10-18 Craig Boulton Dosage regimen of an s1p receptor modulator
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
PT2672823T (pt) 2011-02-07 2016-11-21 Biogen Ma Inc Agentes que modulam s1p
MX2014004813A (es) 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
CN104144927B (zh) * 2011-12-23 2016-08-24 明治制果药业株式会社 S1p受体调节剂
WO2014025709A1 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
EP2879674B1 (en) 2012-08-06 2017-11-22 Biogen MA Inc. Compounds that are s1p modulating agents and/or atx modulating agents
ES2636596T3 (es) 2012-11-20 2017-10-06 Biogen Ma Inc. Agentes moduladores de S1P y/o ATX
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
CN105026360B (zh) 2013-01-29 2017-08-25 比奥根Ma公司 S1p调节剂
WO2014152725A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. S1p and/or atx modulating agents
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 雌激素上调内皮系统保护分子鞘氨醇1-磷酸的应用
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3443986A1 (en) 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CZ284650B6 (cs) 1993-12-17 1999-01-13 Novartis Ag Nové demethoxyderiváty rapamycinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
WO1996006068A1 (en) * 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
AU2912997A (en) 1996-06-24 1998-01-14 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1070080A4 (en) * 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
AU2001231710A1 (en) * 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
EP1377593B1 (en) 2001-03-26 2005-12-28 Novartis AG 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant

Also Published As

Publication number Publication date
IL164838A0 (en) 2005-12-18
MXPA04011384A (es) 2005-02-14
EP1955696A2 (en) 2008-08-13
EP1944026A3 (en) 2011-06-01
US20090209495A1 (en) 2009-08-20
CY1108719T1 (el) 2014-04-09
EP1955696A3 (en) 2011-05-25
IL164838A (en) 2013-12-31
SI1505959T1 (sl) 2009-04-30
EP1955696B1 (en) 2014-05-28
DK1505959T3 (da) 2009-02-23
IL229559A0 (en) 2014-01-30
JP2013136584A (ja) 2013-07-11
BR0311173A (pt) 2005-03-15
PT1505959E (pt) 2009-02-05
DE60324416D1 (de) 2008-12-11
IL229550A0 (en) 2014-01-30
EP1505959B1 (en) 2008-10-29
NO20045312L (no) 2004-12-03
CA2483594A1 (en) 2003-11-27
PL372103A1 (en) 2005-07-11
NO20130106L (no) 2004-12-03
EP1944026A2 (en) 2008-07-16
NZ560662A (en) 2009-09-25
CN1652757A (zh) 2005-08-10
ES2316758T3 (es) 2009-04-16
NZ536513A (en) 2007-10-26
EP1944026B1 (en) 2013-06-26
WO2003097028A1 (en) 2003-11-27
AU2003240655B2 (en) 2007-09-06
KR20120125398A (ko) 2012-11-14
AU2003240655A1 (en) 2003-12-02
JP5227492B2 (ja) 2013-07-03
EP1505959A1 (en) 2005-02-16
HK1073606A1 (en) 2005-10-14
CA2483594C (en) 2011-02-15
CN1652757B (zh) 2012-02-08
NO334074B1 (no) 2013-12-02
US20140303257A1 (en) 2014-10-09
HK1126127A1 (en) 2009-08-28
JP2010100637A (ja) 2010-05-06
JP2005529921A (ja) 2005-10-06
ZA200408575B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
ATE412408T1 (de) Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
TWI372628B (en) Methods of modulating cytokine activity; related reagents
EP1487436A4 (en) POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
BR0316229A (pt) Métodos de tratamento de câncer e métodos relacionados
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
DE69839639D1 (en) Raf kinase hemmer
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
ATE438719T1 (de) Spezifischer marker für prostatakrebs
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DE69942031D1 (de) In prostatakrebs exprimiertes gen
ITMI991605A0 (it) Follatore per il trattamento di cuoio pelli e simili
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
WO2004031775A3 (en) Method for treating or preventing metastasis of colorectal cancers
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
WO2002056753A3 (en) P27 prevents cellular migration
AU2228299A (en) Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
WO2003091690A3 (en) Cancer-associated nucleic acids and polypeptides
WO2003004631A3 (en) USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS.
CY1114433T1 (el) Χρηση παραγοντων που προσδενονται στον υποδοχεα edg στον καρκινο

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1505959

Country of ref document: EP